Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Reaches New 52-Week Low at $9.33

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) reached a new 52-week low on Monday . The company traded as low as $9.33 and last traded at $9.58, with a volume of 383951 shares changing hands. The stock had previously closed at $9.71.

Shionogi & Co., Ltd. Trading Down 1.3 %

The company has a 50 day moving average of $10.90 and a 200 day moving average of $11.78. The firm has a market cap of $11.36 billion, a price-to-earnings ratio of 10.01, a price-to-earnings-growth ratio of 2.71 and a beta of 0.25. The company has a current ratio of 5.86, a quick ratio of 5.37 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) last announced its quarterly earnings results on Monday, May 13th. The company reported $0.21 earnings per share (EPS) for the quarter. The firm had revenue of $662.08 million during the quarter. Shionogi & Co., Ltd. had a net margin of 37.29% and a return on equity of 13.20%. As a group, research analysts anticipate that Shionogi & Co., Ltd. will post 0.87 EPS for the current year.

About Shionogi & Co., Ltd.

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.